Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Reflux esophagitis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    45 result(s) found for: Reflux esophagitis. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2004-000492-33 Sponsor Protocol Number: BY1023/M3-904 Start Date*: 2004-09-06
    Sponsor Name:ALTANA Pharma AG
    Full Title: Healing of patients suffering from gastroesophageal reflux esophagitis grade C-D according to Los Angeles classification after treatment with pantoprazole-magnesium dihydrate 80 mg o.d. in comparis...
    Medical condition: Gastroesophageal reflux esophagitis
    Disease: Version SOC Term Classification Code Term Level
    5.0 10038263 llt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000493-32 Sponsor Protocol Number: BY1023/M3-906 Start Date*: 2004-08-17
    Sponsor Name:ALTANA Pharma AG
    Full Title: Healing of patients suffering from gastroesophageal reflux esophagitis grade A-D according to Los Angeles classification after treatment with pantoprazole-magnesium dihydrate 80 mg o.d. in comparis...
    Medical condition: Gastroesophageal reflux esophagitis
    Disease: Version SOC Term Classification Code Term Level
    5.0 10038263 llt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-004806-25 Sponsor Protocol Number: BY1023/M3-339 Start Date*: 2005-04-25
    Sponsor Name:ALTANA Pharma AG
    Full Title: Evaluation of the complete remission rates in patients with symptomatic non-erosive reflux disease (NERD) or erosive gastroesophageal reflux disease (GERD) treated with pantoprazole 40 mg o.d. ove...
    Medical condition: Gastroesophageal reflux disease
    Disease: Version SOC Term Classification Code Term Level
    5.0 10038263 llt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-013080-19 Sponsor Protocol Number: 27538 Start Date*: 2010-03-31
    Sponsor Name:AMC
    Full Title: Prokinetics to alter the position of the gastric acid pocket in Gastro Esophageal Reflux Disease
    Medical condition: gastro-esophageal reflux disease (GERD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000479 Acid reflux (oesophageal) LLT
    9.1 10017884 Gastrooesophageal reflux LLT
    9.1 10017885 Gastrooesophageal reflux disease LLT
    9.1 10038262 Reflux esophagitis LLT
    9.1 10020024 Hiatal hernia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001526-13 Sponsor Protocol Number: 23/2008/O/Sper Start Date*: 2008-06-03
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Efficacy of Gaviscon in the treatment of gastroesophageal reflux in preterm newborns
    Medical condition: gastroesophageal reflux in preterm newborns
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038262 Reflux esophagitis LLT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002934-12 Sponsor Protocol Number: 77/2007/U/Sper Start Date*: 2007-06-12
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: MANTEINANCE TREATMENT IN NERD PATIENT. A COMPARATIVE RANDOMIZED OPEN STUDY BETWEEN ALGINATE AND MAGALDRATE.
    Medical condition: Gastroesophageal reflux
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038263 Reflux oesophagitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000711-10 Sponsor Protocol Number: BY1023/UK506 Start Date*: 2005-07-07
    Sponsor Name:ALTANA Pharma Ltd.
    Full Title: Determination of the performance characteristics of ReQuestTM in Practice in the stepped down management of GORD
    Medical condition: Gastro-oesophageal reflux disease
    Disease: Version SOC Term Classification Code Term Level
    5.0 10038263 llt
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-001302-16 Sponsor Protocol Number: IKP103/2008 Start Date*: 2008-06-30
    Sponsor Name:Medical Faculty, Otto-von-Guericke University
    Full Title: Stereoselective pharmacokinetics and CYP2C19-genotyping as outcome predictors of an esomeprazole therapy in patients with GERD -- a pilot study (phase IV-study)
    Medical condition: The presented study has to evaluate whether an optimized individual dosage of proton pump inhibitors, adjusted to CYP2C19 genotype, leads to a better pharmacokinetic effect (pH metric acid suppress...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038263 Reflux oesophagitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017229-20 Sponsor Protocol Number: KCT 27/2009 – PAN-STAR/PL Start Date*: 2010-06-24
    Sponsor Name:KRKA-POLSKA Sp. z o.o.
    Full Title: Efficacy and safety of PANtoprazole in the treatment and SympTom relief in patients with gAstRoesophageal reflux disease (GERD) – PAN-STAR
    Medical condition: gastroesophageal reflux disease (GERD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066874 Gastroesophageal reflux disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-004232-29 Sponsor Protocol Number: UZBLANREOTIDE01 Start Date*: 2014-01-02
    Sponsor Name:UZ Brussel
    Full Title: A phase II proof of concept study to evalute the efficacy and safety of deep subcutaneous lanreotide Autogel 120 mg / 28 days on symptoms and healing of the esophageal and gastric mucosa in patient...
    Medical condition: patients with persistent endoscopic reflux in spite of maximal medical therapy with PPI 2 x 40 mg pantoprazole before breakfast and dinner and 300 mg of H2 blocker ranitidine at bedtime AND continu...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004856 10017924 Gastroesophageal reflux LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000926-30 Sponsor Protocol Number: BY1023/M3-343 Start Date*: Information not available in EudraCT
    Sponsor Name:ALTANA Pharma AG
    Full Title: Investigation of clinical endpoints for treatment-induced gastroesophageal reflux disease (GERD) symptom changes
    Medical condition: gastroesophageal reflux disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10017885 Gastrooesophageal reflux disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-001681-15 Sponsor Protocol Number: TAK-390MR_207 Start Date*: 2012-10-17
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd
    Full Title: A Phase 2 Multicenter, 36-Week Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenan...
    Medical condition: Heartburn and Erosive Esophagitis in Adolescent Subjects
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10018203 GERD LLT
    14.1 10017947 - Gastrointestinal disorders 10019326 Heartburn LLT
    14.1 10017947 - Gastrointestinal disorders 10063657 Erosive esophagitis LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002031-92 Sponsor Protocol Number: EX0307 Start Date*: Information not available in EudraCT
    Sponsor Name:Otto-von-Guericke University
    Full Title: Proliferation and differentiation markers, involved in erosive and non-erosive reflux esophagitis, Barrett´s esophagus and esophageal adenocarcinoma.
    Medical condition: Dyspeptic Symptoms GERD (gastroesophageal reflux disease), NERD (non erosive reflux disease), ERD (erosive reflux disease), Barretts esophagus, Adeno-CA of the esophagus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017885 Gastrooesophageal reflux disease PT
    9.1 10004137 Barrett's oesophagus PT
    9.1 10001173 Adenocarcinoma of esophagus LLT
    9.1 10013949 Dyspeptic signs and symptoms HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019563-11 Sponsor Protocol Number: RB10001 Start Date*: 2010-06-01
    Sponsor Name:RECKITT BENCKISER HEALTHCARE
    Full Title: Etude de non-infériorité de l’efficacité de Gaviscon suspension buvable en flacon versus Oméprazole 20mg sur le pyrosis chez des patients ayant un RGO dont l’épisode actuel n’est pas traité.
    Medical condition: Patient volontaire présentant un épisode de RGO non traité et venant consulter en médecine générale.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10017924 Gastroesophageal reflux LLT
    12.1 10017885 Gastrooesophageal reflux disease LLT
    12.1 10017933 Gastrointestinal atonic and hypomotility disorders NEC HLT
    12.1 10063655 Erosive oesophagitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002370-39 Sponsor Protocol Number: D9614C00097 Start Date*: 2004-12-02
    Sponsor Name:ASTRAZENECA
    Full Title: A Phase III, Multicentre, Randomized, Double-blind Parallel-group Study to Evaluate the Safety and Clinical Outcome of Once Daily Esomeprazole for the Treatment of Gastroesophageal Reflux Disease ...
    Medical condition: Gastroesophageal Reflux Disease GERD
    Disease: Version SOC Term Classification Code Term Level
    6.1 10017885 PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-003485-42 Sponsor Protocol Number: BY1023/M3-341 Start Date*: 2006-03-24
    Sponsor Name:ALTANA Pharma AG
    Full Title: Treatment response in patients with symptoms due to gastroesophageal reflux disease either with or without esophagitis treated with pantoprazole sodium 40 mg o.d. over 8 weeks
    Medical condition: gastroesophageal reflux disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10017885 llt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) ES (Completed) GB (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000927-33 Sponsor Protocol Number: BY1023/M3-342 Start Date*: 2006-05-03
    Sponsor Name:Nycomed GmbH
    Full Title: Confirmation of superiority of complete remission concept vs classical healing concept for treatment of patients with erosive GERD
    Medical condition: gastroesophageal reflux disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10017885 Gastrooesophageal reflux disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004506-15 Sponsor Protocol Number: TAK-390MR_204 Start Date*: 2015-12-10
    Sponsor Name:Takeda Development Centre Europe Ltd.
    Full Title: A Phase 2, Double-Blind, 12 Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules in Pediatric Subjects Aged 1 to ...
    Medical condition: Symptomatic nonerosive GERD in paediatric subjects aged 1 to 11 years
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004856 10066874 Gastroesophageal reflux disease LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) IT (Prematurely Ended) PT (Completed) PL (Trial now transitioned) LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002777-42 Sponsor Protocol Number: BY359/M3-301 Start Date*: 2006-11-07
    Sponsor Name:ALTANA Pharma AG
    Full Title: Endoscopic healing and tolerability of Soraprazan 20 mg qd compared to Soraprazan 10 mg qd and to Esomeprazole 40 mg qd in patients suffering from GERD Grade A-D (LA classification)
    Medical condition: Endoscopically confirmed gastroesophageal reflux disease (GERD), Grade A-D according to Los Angeles (LA) classification
    Disease: Version SOC Term Classification Code Term Level
    8.1 10018203 GERD LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-003319-91 Sponsor Protocol Number: CX842A2201 Start Date*: 2021-02-08
    Sponsor Name:Cinclus Pharma AG
    Full Title: A randomized double-blind, double dummy, active comparator-controlled dose finding study in patients with reflux esophagitis Los Angeles grade C or D, and patients with at least partial symptom res...
    Medical condition: reflux esophagitis Los Angeles grade C or D and patients with grades A or B who partially responded to PPI patients with grades A or B who partially responded to PPI
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10038262 Reflux esophagitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 01:46:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA